You are here

MAPCs for Hypoxic-ischemic Cerebellar Injury

A recent STEM CELLS Translational Medicine article from researchers led by Reint K. Jellema (Maastricht University Medical Center, The Netherlands) described the reduction of cerebellar injury after asphyxia following systemic multipotent adult progenitor cell (MAPC) therapy. These findings extend their previous research that established how MAPC treatment could induce structural and functional neuroprotection after asphyxia in the ovine cerebrum. Overall, Gussenhoven et al. anticipate that this relevant large animal model study with clinical‐grade stem cells improves the potential for translation into neonatal medicine.